First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Moderate Buy” from Analysts

First Tracks Biotherapeutics (NASDAQ:TRAX) has earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $40.00.

TRAX has been the topic of a number of research reports. JPMorgan Chase & Co. assumed coverage on shares of First Tracks Biotherapeutics in a report on Thursday, April 23rd. They set an “overweight” rating and a $31.00 target price on the stock. HC Wainwright boosted their price target on shares of First Tracks Biotherapeutics from $30.00 to $44.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. Barclays assumed coverage on First Tracks Biotherapeutics in a research report on Wednesday, April 22nd. They set an “overweight” rating and a $40.00 price objective on the stock. Wells Fargo & Company assumed coverage on First Tracks Biotherapeutics in a research note on Monday, June 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. Finally, Wall Street Zen upgraded First Tracks Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd.

First Tracks Biotherapeutics Trading Up 0.8%

NASDAQ TRAX opened at $36.51 on Friday. The stock has a market capitalization of $1.27 billion and a price-to-earnings ratio of -19.84. The company has a 50 day simple moving average of $19.98. First Tracks Biotherapeutics has a one year low of $14.72 and a one year high of $39.67.